These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 35941634)

  • 21. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
    Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
    Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of CalliSpheres
    Jin B; Gu Y; Xi S; Liu X; Wu X; Wang X; Li G
    Scand J Gastroenterol; 2024 Sep; 59(9):1087-1092. PubMed ID: 39154241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma].
    Chen G; Zhang D; Ying Y; Wang Z; Tao W; Zhu H; Zhang J; Peng Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):44-51. PubMed ID: 28436630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
    Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
    J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.
    Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J
    Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
    Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
    J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.
    Schindler P; Kaldewey D; Rennebaum F; Trebicka J; Pascher A; Wildgruber M; Köhler M; Masthoff M
    J Cancer Res Clin Oncol; 2024 May; 150(5):235. PubMed ID: 38710956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
    Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
    Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W; Chen C
    Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of CalliSpheres
    Liu Y; Huang W; He M; Lian H; Guo Y; Huang J; Zhou J; Zhu K
    Oncol Res; 2019 May; 27(5):565-573. PubMed ID: 30005719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres
    Peng Z; Cao G; Hou Q; Li L; Ying S; Sun J; Zhou G; Zhou J; Zhang X; Ji W; Yu Z; Li T; Zhu D; Hu W; Ji J; Du H; Shi C; Guo X; Fang J; Han J; Gu W; Xie X; Sun Z; Xu H; Wu X; Hu T; Huang J; Hu H; Zheng J; Luo J; Chen Y; Yu W; Shao G
    Oncol Res; 2020 May; 28(3):249-271. PubMed ID: 31856933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study.
    Xiang H; Xiong B; Li H; Zhao C; Zhang Z; Ma C; Zheng C; Luo C; Qiu H; Yao Y; Hu H; Zhao H; Long Q; Zhou J; Chen C; Ma Y
    Transl Cancer Res; 2019 Sep; 8(5):1950-1964. PubMed ID: 35116944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
    Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
    Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.
    Duan X; Li H; Chen P; Sun T; Kuang D; Lu H; Qiao B; Fan Z; Ren Z; Han X
    Eur Radiol; 2024 Feb; 34(2):1258-1267. PubMed ID: 37581654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
    Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
    Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.